id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-289079-m417oxpc	Waggershauser, Constanze H.	Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area	2020-08-14		.txt	text/plain	405	35	58	Editors, With interest, we read the article of Taxonera et al on symptoms and the risk of COVID-19 in inflammatory bowel disease (IBD). 1 We would like to provide data from our IBD centre during the outbreak of SARS-CoV-2 concerning patients receiving immunotherapies. 2 Therefore, soon two questions raised great concern: are IBD patients who receive immunotherapies more susceptible to SARS-CoV-2 infections than the general population and are infected patients exposed to a more severe course? Since the estimated number of silent SARS-CoV-2 infections is high 7 and most individuals show only moderate symptoms of respiratory tract infection, we called or invited our patients to fill-in a questionnaire, 8 Our data confirm the recommended practice that immunotherapies should not be stopped or delayed during the COVID-19 crisis. Daniel Szokodi has served as a speaker for Pfizer. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases	./cache/cord-289079-m417oxpc.txt	./txt/cord-289079-m417oxpc.txt